ArticleFrontiers in neuroscience2025
Association between serum sodium and sporadic Parkinson's disease.
Article in Frontiers in neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The correlation between serum sodium and sporadic Parkinson's disease remains unclear currently. This study aimed to assess the association between serum sodium and sporadic Parkinson's disease. Objective: The ultimate goal is to gain a deeper understanding of the implications of this relationship between serum sodium and sporadic Parkinson's disease. Methods: We conducted a retrospective cross-sectional study involving 1,189 participants in PPMI cohort. Age, sex, education years, race, body mass index, calcium, alanine aminotransferase, aspartate aminotransferase, white blood cell, lymphocytes, neutrophils, monocytes, red blood cell, hemoglobin, platelets, total protein, albumin, serum uric acid, serum sodium, serum potassium, urea nitrogen, creatinine, serum glucose were obtained from all participants. Logistic regression, and smooth curve fitting were utilized to substantiate the research objectives. Results: The overall sporadic Parkinson's disease was 77.5% (921/1189); it was 71.9% (143/199), 75.4% (295/391), 76.7% (171/223), and 83% (312/376) for serum sodium quantile1 (Q1, 130-138.9 mmol/L), quantile 2 (Q2, 139-140.9 mmol/L), quantile 3 (Q3, 141-141.9 mmol/L), and quantile 4 (Q4, 142-155 mmol/L), respectively ( Conclusion: This study highlights the influence of inappropriate serum sodium on the risk of incident sporadic Parkinson's disease, independent of confounders. The link between serum sodium and sporadic Parkinson's disease is linear.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.